Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TGF beta 1 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. [1] It was dropped from further development in favour of fresolimumab, [2] which was being developed by Genzyme as of 2006. [3]
Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies. [4] [5]
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made. [6]
Initial trials targeted the skin condition scleroderma [7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab, [2] which was being developed by Genzyme as of 2006. [3]
{{
cite journal}}
: Cite journal requires |journal=
(
help)